PEPTIDE GUIDE

What Is TB-500?

TB-500 is a name used for a synthetic seven-amino-acid peptide related to thymosin beta-4, a natural 43-amino-acid peptide found in many human cells. The short fragment is usually identified as acetyl-LKKTETQ, written Ac-LKKTETQ.

Most published tissue-repair research concerns full-length thymosin beta-4, not the seven-amino-acid TB-500 fragment. Treating those molecules as though they have the same clinical evidence produces a misleading picture of what is known.

Research statusExperimental fragment with no established human clinical evidence
Defined fragmentAc-LKKTETQ, seven amino acids
Parent peptideThymosin beta-4, 43 amino acids
Human evidenceNo established clinical evidence for the fragment
Last reviewed17 November 2026
THE SHORT ANSWER

TB-500 is generally identified as an acetylated seven-amino-acid fragment of thymosin beta-4. Full-length thymosin beta-4 binds actin, a structural protein involved in cell shape and movement, and has been investigated in laboratory, animal and topical human studies of tissue and eye repair. The TB-500 fragment itself does not have an established programme of human clinical trials. The US Food and Drug Administration, normally shortened to FDA, states that it has not identified human exposure data for compounded products containing the fragment. Thymosin beta-4 and its derivatives, including TB-500, are prohibited at all times in regulated sport.

Are TB-500 and thymosin beta-4 the same?

No. Full-length human thymosin beta-4 contains 43 amino acids. The material identified by World Anti-Doping Agency researchers as TB-500 is the acetylated sequence LKKTETQ, corresponding to positions 17 to 23 within the longer peptide.

Some sellers use “TB-500” for the fragment, some use it for full-length thymosin beta-4 and others do not provide a verifiable sequence. A product name therefore cannot establish which molecule is present. This guide uses TB-500 for the seven-amino-acid fragment and thymosin beta-4 for the full-length peptide.

The difference affects the evidence. A trial of a regulated eye drop containing full-length thymosin beta-4 cannot establish that a separately manufactured fragment has the same absorption, distribution, activity or safety. A mouse experiment using recombinant full-length peptide also does not validate an online vial carrying the TB-500 label.

What is thymosin beta-4?

Thymosin beta-4 is a naturally occurring peptide present in many tissues and cell types. It belongs to the beta-thymosin family and is especially abundant in platelets, which are small blood components involved in clotting and the early response to injury.

One of its best-established biochemical roles is binding globular actin, normally called G-actin. Actin can exist as individual units or assemble into filaments that help cells maintain their shape, move and reorganise after damage. Thymosin beta-4 holds a pool of individual actin units and influences when those units are available for filament formation.

That actin biology gives researchers a reasonable mechanism to investigate. It does not prove that administering thymosin beta-4 or TB-500 repairs an injured tendon or muscle in a person. Repair involves blood supply, inflammation, mechanical loading, scar formation and many other signals.

How does normal tissue repair work?

The word healing can make several different biological processes sound like one event. In practice, damaged tissue moves through overlapping stages. The balance between those stages affects whether the final tissue regains useful strength and movement or is left with pain, weakness or excessive scar tissue.

The first stage is haemostasis, when bleeding is controlled. Platelets gather at the damaged area and help form a clot. Platelets also release chemical signals that attract immune cells and other repair cells. Thymosin beta-4 is present in platelets, but its presence at an injury does not show that adding more from outside the body will improve the result.

Inflammation follows. Immune cells remove damaged material and help defend the wound against infection. Inflammation is often described as something that should simply be suppressed, but an early inflammatory response is part of normal repair. The problem is persistent or poorly controlled inflammation, which can delay rebuilding and increase tissue damage.

During the proliferative stage, cells multiply and move into the injured area. Fibroblasts, which are cells that make connective-tissue material, produce an early framework. New small blood vessels can grow into the area, a process called angiogenesis. In a skin wound, keratinocytes move across the surface to restore the protective outer layer.

Remodelling is the slower final stage. Early collagen is reorganised and replaced, fibres become better aligned with the forces placed upon them and the tissue gradually gains strength. Tendons and ligaments can take months to remodel because they have a dense collagen structure and a relatively limited blood supply. A treatment that changes a tissue sample at four weeks has not necessarily restored normal function or prevented re-injury months later.

Thymosin beta-4 research touches several of these stages. Studies have examined cell migration, blood-vessel formation, inflammatory signalling, collagen organisation and cell survival. A credible treatment claim would still need to show that these biological changes produce better pain, strength, function and return to activity in people.

What is TB-500 made from?

The TB-500 fragment is made from seven amino-acid building blocks: leucine, lysine, lysine, threonine, glutamic acid, threonine and glutamine. The beginning of the chain is acetylated, meaning that a small acetyl chemical group is attached to the first amino acid.

The sequence is written Ac-LKKTETQ. Each letter represents one amino acid. The same seven-amino-acid region appears within natural thymosin beta-4, but an isolated fragment does not automatically reproduce every action of the complete peptide.

Full-length thymosin beta-4 can be made by chemical peptide synthesis or by recombinant production. Recombinant production uses genetically instructed cells to make the peptide. The cells are grown under controlled conditions, the product is separated from the culture material and it is purified and tested.

When were thymosin beta-4 and TB-500 first documented?

Thymosin research began with extracts prepared from the thymus gland during the 1960s. Researchers later found that the material called “thymosin” contained multiple small proteins and peptides rather than one hormone. Thymosin beta-4 was isolated, sequenced and recognised as a widely distributed peptide during the following decades.

Research on its actin-binding role and possible repair functions expanded during the 1980s and 1990s. A 1999 rat study reported faster closure of full-thickness skin wounds after full-length thymosin beta-4 treatment. Later programmes examined dermal wounds and eye conditions.

TB-500 emerged much later as a product name in equine and human performance markets. A World Anti-Doping Agency-funded project approved in 2013 reported that the active content had been identified as the acetylated 17-to-23 fragment of thymosin beta-4.

PeriodDevelopment
1960sThymic extracts called thymosins began to be studied
1980sThymosin beta-4 was characterised as a distinct peptide and actin-binding protein
1990sExperimental wound-repair research expanded
1999A rat full-thickness wound study reported faster healing with full-length thymosin beta-4
2003Full-length thymosin beta-4 and a seven-amino-acid LKKTETQ peptide were studied in diabetic and aged mice
2010sAnti-doping researchers characterised TB-500 as Ac-LKKTETQ
2010 to 2021Full-length synthetic and recombinant thymosin beta-4 entered topical and intravenous human studies
2025A randomised study reported results for recombinant full-length thymosin beta-4 in 96 heart-attack patients
2026A rat Achilles-tendon study used a commercial product labelled TB-500, while a separate mouse colitis paper tested recombinant full-length thymosin beta-4

How is TB-500 synthesised and manufactured?

The seven-amino-acid fragment is short enough for solid-phase peptide synthesis. In this method, the first protected amino acid is attached to an insoluble resin. Additional protected amino acids are joined in the required order through peptide bonds, the chemical links that connect amino acids.

Temporary protecting groups prevent each building block from reacting in the wrong place. After the sequence has been assembled, the peptide is removed from the resin, the remaining protecting groups are cleared and the N-terminal acetyl group is added or retained as required by the manufacturing route.

The crude product contains the intended sequence alongside incomplete chains, deletion sequences and chemical by-products. Preparative liquid chromatography separates these materials. Mass spectrometry and analytical chromatography can then test identity and purity. Manufacturing a peptide of the correct mass does not by itself establish sterility, freedom from endotoxin, stability or suitability for administration.

Full-length 43-amino-acid thymosin beta-4 requires a longer process. It may be assembled chemically or produced in a recombinant expression system. The 2026 colitis study used recombinant human thymosin beta-4. That description refers to full-length laboratory-produced material, not to Ac-LKKTETQ.

How might full-length thymosin beta-4 affect repair biology?

Laboratory work has examined several connected processes. Thymosin beta-4 can influence actin organisation and cell migration. Cell migration is the movement of cells into an area where repair is taking place. Studies have also reported effects on new blood-vessel formation, inflammatory signalling, cell survival and scar-related pathways.

These observations come from different models. A cultured cell provides information about a narrow molecular response. A deliberately created wound in a mouse or rat shows how several biological systems behave together. Neither reproduces a human sports injury, chronic tendon disorder or post-operative recovery.

The central LKKTET region participates in actin binding, which is one reason the shorter fragment attracted interest. However, retaining a functional region does not show that the fragment reaches the same tissues, lasts as long or produces the same overall response as full-length thymosin beta-4.

What have animal wound and injury studies found?

Animal studies have reported faster dermal wound closure, changes in inflammation and repair in injured corneas, and changes in ligament healing. The models often use full-length thymosin beta-4 locally or systemically under controlled laboratory conditions.

A medial collateral ligament study, for example, surgically divided the ligament in rats and then assessed repair. That is useful for examining tissue organisation and strength in a standardised injury, but it is not equivalent to a naturally occurring ligament sprain in a person.

Positive animal findings justify further research. They do not establish how much benefit a human would experience, which injuries might respond, whether the fragment works, or whether repeated systemic exposure would be safe.

What fragment-specific wound evidence exists?

A 2003 study is particularly relevant because it did not examine only the 43-amino-acid parent peptide. Researchers created full-thickness skin wounds in diabetic mice and aged mice, two models in which healing is normally delayed. They tested full-length thymosin beta-4 and also a synthetic seven-amino-acid peptide containing the actin-binding LKKTETQ region.

In the aged mice, the seven-amino-acid peptide promoted measures of wound repair to a degree the researchers described as comparable with the parent molecule. The study assessed features including movement of keratinocytes across the wound, wound contraction and collagen deposition. Collagen is the main structural protein in skin, tendon and ligament.

This experiment gives the short sequence more direct biological support than a study using only full-length thymosin beta-4. It still leaves several limits. The animals were mice, the injuries were controlled skin wounds and the paper described LKKTETQ rather than a general programme of systemic TB-500 treatment. A result in aged mouse skin cannot establish recovery from a human tendon rupture, muscle tear or joint injury.

The chemical form also needs attention. Commercial TB-500 is generally described as N-terminally acetylated Ac-LKKTETQ. A paper must report the exact sequence, terminal modifications, route and formulation before its result can be transferred to that defined molecule.

What did the 2026 rat Achilles-tendon study find?

This is the most directly relevant recent study for the recovery claims surrounding TB-500. Researchers in Türkiye surgically cut and repaired the Achilles tendons of 32 healthy male rats. The Achilles tendon connects the calf muscles to the heel bone and is the largest tendon in the human body.

The rats were randomly divided into four groups of eight: an untreated control group, a BPC-157 group, a TB-500 group and a group receiving both products. Random allocation means the group was decided by chance rather than selected by the researchers. This helps reduce systematic differences between the groups at the start of an experiment.

The paper reported daily intraperitoneal administration for 30 days. Intraperitoneal means the material was placed into the abdominal cavity. The TB-500 level was 60 micrograms per kilogram of body weight per day. That level is included only to identify the animal experiment. It is not a human dose, and a body-weight calculation cannot convert it into one.

After four weeks, the researchers removed the repaired tendons. Half of the tendons in each group were allocated to mechanical testing and half to tissue analysis. The effective sample was therefore only four tendons per group for many outcomes.

The TB-500 group had a higher maximum load to failure than the control group. Maximum load to failure is the greatest pulling force the repaired tendon tolerated before it broke during laboratory testing. Tissue scoring also favoured the TB-500 group for several measures, including collagen alignment and overall tendon organisation. Combining BPC-157 and TB-500 did not produce a clear additional benefit.

These results are interesting, but they do not amount to human evidence. The study used young, healthy rats with a clean surgical cut followed by immediate repair. It measured one four-week time point and did not assess pain, walking, return to sport or later re-injury. It also used only four specimens per group for several analyses, which makes the estimates less stable.

There is a further identity problem. The researchers named the material “synthetic thymosin beta-4 (TB-500)” and gave a commercial catalogue number, but the published methods did not report its amino-acid sequence, molecular mass or certificate of analysis. The level was selected from the broader full-length thymosin beta-4 literature because the authors said tendon-specific optimisation studies for TB-500 were absent. Readers therefore cannot confirm from the paper alone whether the product was Ac-LKKTETQ, full-length thymosin beta-4 or another material sold under the same name.

The paper is best treated as an exploratory animal result. It supports replication with a chemically defined product, larger groups, multiple time points, functional outcomes and longer follow-up. It does not establish that TB-500 speeds human Achilles-tendon recovery.

What did the rat ligament study show?

A 2013 study sharply divided the medial collateral ligament in rats. The medial collateral ligament, usually shortened to MCL, runs along the inner side of the knee and helps resist forces that push the knee sideways.

Researchers placed a fibrin sealant containing 1 microgram of full-length thymosin beta-4 into the ligament gap. Fibrin sealant is a clot-like surgical material that can hold a test substance at the injury. Four weeks later, the treated ligaments showed more evenly organised fibre bundles, larger collagen fibrils and better mechanical properties than control ligaments.

This was a local full-length-peptide experiment, not a study of systemic Ac-LKKTETQ. It also involved a deliberately cut rat ligament rather than a human sprain treated through normal rehabilitation. The result supports a possible effect on connective-tissue organisation, but it cannot provide a human recovery estimate.

What does the muscle research show?

Muscle research provides a useful example of why a plausible mechanism is not enough. A 2011 study found that injured mouse muscle produced more thymosin beta-4. In cell experiments, the peptide attracted myoblasts, which are immature muscle cells that can move into damaged areas and contribute to repair. This supports a role for naturally produced thymosin beta-4 in the injury response.

A later study examined thymosin beta-4 as an exerkine. An exerkine is a molecule released by tissues during exercise that may carry signals to other cells or organs. The researchers found increased thymosin beta-4 in laboratory muscle cells when they contracted and detected release from human muscle tissue.

However, giving thymosin beta-4 to mice did not improve muscle regeneration in that experiment. It also did not correct the metabolic effects of diet-induced obesity. The negative in-vivo finding matters because it shows that increased production during exercise and effects on isolated cells do not guarantee better repair in a whole animal.

Neither study tested the seven-amino-acid TB-500 fragment in injured people. There is no controlled human evidence showing that it reduces soreness, restores strength or shortens return to activity after a muscle tear.

Has thymosin beta-4 been studied in bone repair?

Full-length thymosin beta-4 has also been tested in mouse fracture models. A 2014 study reported changes in new blood-vessel formation, callus development and fracture healing after experimental administration. A callus is the temporary tissue bridge that forms around a healing break before it is remodelled into stronger bone.

Bone repair is not the same as tendon or muscle repair. The study was preclinical, used full-length peptide and did not test the commercial fragment. It broadens the parent peptide's research record without establishing a treatment for human fractures.

What did the 2026 colitis study find?

The August 2026 paper examined recombinant human thymosin beta-4 in experimental mouse models of colitis and intestinal fibrosis. Colitis means inflammation of the large intestine. Fibrosis is the build-up of scar-like tissue after persistent injury.

The researchers reported improvements in disease measures and linked the findings to suppression of mineralocorticoid receptor signalling. A receptor is a protein that receives a chemical signal. Mineralocorticoid receptors are better known for roles in salt balance and blood pressure, but they can also participate in inflammation and fibrosis.

This was preclinical research. It did not test people with ulcerative colitis or Crohn's disease. It used full-length recombinant thymosin beta-4, not the seven-amino-acid TB-500 fragment. It therefore adds an experimental direction for the parent peptide but provides no clinical evidence for a TB-500 product.

Has full-length thymosin beta-4 been tested in people?

Yes, but the human programmes used specific formulations of full-length thymosin beta-4. The clearest published work concerns topical eye drops and wound products. It does not establish systemic injury-recovery benefits.

A small Phase 2 dry-eye trial enrolled nine people with severe disease. Participants were randomly assigned to 0.1% RGN-259 eye drops or a vehicle control, meaning matching drops without the active peptide. The drops were used six times daily for 28 days, with follow-up to day 56. The study reported improvements in ocular discomfort and corneal staining, but the sample was extremely small.

Larger eye programmes followed. Public reports describe mixed Phase 3 development, including trials that did not meet their main prespecified outcome. A prespecified outcome is the result chosen before data are analysed. Findings from one subgroup or later pooled analyses are weaker than a clearly successful primary outcome.

Dermal studies have also examined full-length thymosin beta-4 in chronic wounds. Reviews describe pressure-ulcer, venous-stasis-ulcer and epidermolysis-bullosa programmes, but published detail is limited and no broadly approved medicine resulted.

Study design, not dosing guidance

The 0.1% eye-drop concentration, six-times-daily schedule and 28-day duration describe one regulated topical study in nine people. They are included so readers can understand what was tested. They are not instructions for using TB-500 or thymosin beta-4, and they do not translate to an injectable product.

What did the human skin-wound studies find?

The best-described controlled dermal study involved 73 adults with venous stasis ulcers at eight European centres. A venous stasis ulcer is a persistent lower-leg wound associated with poor return of blood through the veins. These wounds are not comparable with an acute tendon strain or surgical muscle injury.

Participants were randomly assigned to a topical gel containing full-length thymosin beta-4 at one of three concentrations or to a matching gel without the active peptide. All groups also received standard wound care, including compression. Compression addresses the underlying venous problem and is therefore an important part of the comparison.

The study ran for up to 84 days. The investigators reported an acceptable safety profile and the strongest efficacy signal with the 0.03% gel. About one quarter of participants achieved complete healing within three months, particularly when ulcers were smaller or less severe.

The published conclusion was cautious. The study suggested that the 0.03% formulation might accelerate healing and justified further research. It did not establish a general wound-healing indication, and it did not test Ac-LKKTETQ. A topical gel applied directly to an open skin ulcer also creates a very different exposure from a fragment entering the circulation.

This trial is useful because it shows that full-length thymosin beta-4 reached controlled human testing. It should not be presented as a TB-500 clinical trial.

Study levels, not personal guidance

The 0.01%, 0.03% and 0.1% gels and the 84-day study period identify the formulations compared in this Phase 2 trial. They are not instructions for treating a wound or preparing a peptide product.

What did the larger eye studies find?

Eye research is the most developed clinical programme for a specific full-length thymosin beta-4 formulation. RGN-259 is a preservative-free eye-drop product containing full-length thymosin beta-4. It is not the seven-amino-acid TB-500 fragment.

One Phase 2 trial enrolled 72 people with moderate to severe dry eye. Phase 2 studies look for evidence that a treatment may work while continuing to assess safety. Participants were randomly assigned in equal numbers to 0.1% RGN-259 or matching placebo drops for 28 days. A placebo resembles the study treatment but does not contain the active substance, allowing researchers to estimate how much change is attributable to the tested product.

The trial used a controlled adverse environment, an indoor setting designed to worsen dry-eye signs under standardised conditions. The paper reported improvements in selected discomfort and corneal-staining measures. Corneal staining uses a dye to reveal damage on the eye's surface. Results from a controlled exposure room may not perfectly reflect symptoms during normal daily life.

A later Phase 3 study enrolled 18 people with stage 2 or 3 neurotrophic keratopathy. Neurotrophic keratopathy is a rare disorder in which damaged corneal nerves prevent the surface of the eye from healing normally. Six of ten participants using RGN-259 had complete closure of the corneal defect after four weeks, compared with one of eight receiving placebo. The probability value was 0.0656, which did not cross the study's usual 0.05 threshold for statistical significance.

The apparent difference was large, but the sample was very small and the estimate was imprecise. A 2025 systematic review rated the evidence for RGN-259 in this condition as low certainty. Low certainty means further research could substantially change the estimated effect.

This programme shows that a defined full-length formulation can reach later-stage human trials. It does not validate systemic TB-500, and it does not show that an eye-drop result transfers to tendon, ligament or muscle recovery.

Study levels, not personal guidance

The 0.1% concentration and 28-day periods describe regulated topical eye studies. They are not instructions for using thymosin beta-4 or TB-500 by any route.

Has full-length thymosin beta-4 been studied systemically in people?

Yes. This is sometimes overlooked when the human evidence is summarised only through eye and wound studies. The systemic studies still concern full-length thymosin beta-4, not Ac-LKKTETQ.

A 2010 Phase 1 study enrolled four cohorts of ten healthy volunteers. Phase 1 is the first stage of human drug development and focuses mainly on short-term safety, tolerability and how the body handles the material. Participants received a single intravenous infusion of synthetic full-length thymosin beta-4 or placebo. After a safety review, multiple daily infusions were studied for 14 days.

The reported trial levels ranged from 42 to 1,260 milligrams. Adverse events were described as infrequent and mild or moderate, with no serious adverse events or dose-limiting toxicity reported in the paper. Dose-limiting toxicity means a harmful effect serious enough to prevent researchers from increasing or continuing the tested level. The study also measured pharmacokinetics, meaning the movement and removal of the peptide in the body.

A separate 2021 study tested recombinant human thymosin beta-4 called NL005 in healthy volunteers. Recombinant means it was produced by genetically instructed cells rather than assembled one amino acid at a time. Fifty-four participants entered seven single-administration cohorts, covering 0.05 to 25 micrograms per kilogram. Another 30 participants entered three multiple-administration cohorts receiving 0.5, 2 or 5 micrograms per kilogram once daily for ten days, followed for 28 days.

That study examined adverse events, pharmacokinetics and anti-drug antibodies. Anti-drug antibodies are immune proteins that recognise a medicine and can sometimes change its activity or create reactions. The authors reported that NL005 was well tolerated within the short observation period.

These trials show that particular full-length products were administered intravenously under controlled clinical conditions. They cannot establish the safety of an unregulated fragment, a different manufacturing process or longer use. Healthy-volunteer tolerability also does not show that a product repairs an injury.

Study levels, not personal guidance

The administration levels above identify two full-length-peptide safety programmes with very different formulations and units. They are not interchangeable and are not TB-500 recommendations.

What did the 2025 heart-attack study find?

A 2025 paper reported a randomised, double-blind, placebo-controlled study in 96 people who had experienced an ST-segment elevation myocardial infarction, shortened to STEMI. Double-blind means neither the participants nor the clinical researchers knew who was receiving the active product while the trial was under way. This is a serious type of heart attack caused by a blocked coronary artery.

All participants had undergone percutaneous coronary intervention, or PCI, to reopen the artery. PCI normally involves passing a catheter into the coronary artery and using a small balloon and often a stent to restore blood flow. The study asked whether recombinant full-length human thymosin beta-4 could reduce the damage that can continue when blood flow returns.

Participants received placebo or recombinant full-length thymosin beta-4 at 0.5 or 1 microgram per kilogram intravenously each day for seven days. The main imaging assessment measured the area of damaged heart muscle. Across all 96 participants, the change in infarct area and left ventricular ejection fraction was not significantly different between the thymosin beta-4 and placebo groups. Ejection fraction is the percentage of blood pumped out of the heart's main chamber with each contraction.

The researchers then examined treatment timing. Among participants first treated within eight hours after PCI, the 1 microgram per kilogram group had a smaller infarct area at 90 days than placebo, reported as 24.86% compared with 34.73%. This was a later subgroup analysis rather than a positive overall result. A subgroup is a smaller part of the full trial population. Findings from these smaller groups can identify a question for a future trial, but they are less secure because dividing the data creates more opportunities for a chance result.

Measures of heart-chamber volume also favoured the recombinant peptide at some follow-up points, while safety and tolerability findings were described as similar between the groups. A larger trial designed in advance around early treatment would be needed to confirm whether the signal is real and clinically important.

This study adds meaningful human evidence for a defined full-length recombinant medicine candidate. It does not test TB-500, sports recovery or a musculoskeletal injury. Its trial levels should not be transferred to the fragment.

Has the TB-500 fragment been tested in people?

The evidence is much thinner. In its current safety summary, the FDA says it has not identified human exposure data for drug products containing the thymosin beta-4 fragment LKKTETQ.

Anti-doping studies have investigated how the fragment breaks down in human liver preparations, plasma and serum outside the body. Those experiments support detection methods. They do not assess whether administering TB-500 repairs tissue or is safe.

This is the central evidence gap. Human findings for full-length topical thymosin beta-4 cannot be transferred to systemic use of the fragment.

The systemic full-length safety studies do not close that gap. Changing a 43-amino-acid peptide to a seven-amino-acid fragment changes its size, breakdown, distribution and potentially its targets. A human trial of recombinant full-length thymosin beta-4 is evidence for that named investigational product only.

What did Health Canada's November 2026 peptide contamination warning find?

On 12 November 2026, Health Canada reported that laboratory testing had identified *Sphingomonas aquatilis/melonis* bacteria in an injectable peptide product seized from a retailer in Ottawa. The retailer's unauthorised inventory included products labelled TB-500 in combinations with BPC-157. The agency did not say that every product on its inventory list, or every batch of the named compound, tested positive for bacteria.

This is a product-quality and safety finding, not a new clinical trial of the peptide. Bacterial contamination in material intended for injection can cause serious infection, including sepsis. The agency also warned that a label saying 'for research use only' does not demonstrate sterility or make an unauthorised product suitable for human use. The finding cannot be used to estimate contamination rates across the wider market or to judge the quality of material used in controlled clinical studies.

Is there evidence for tendon, ligament or muscle recovery in people?

No dependable human clinical programme has shown that TB-500 accelerates recovery from tendon, ligament or muscle injury.

The claim is built mainly from mechanism research, animal injury models and evidence involving full-length thymosin beta-4. Those sources can explain why researchers are interested. They cannot provide an effect size for a person, identify an appropriate clinical population or establish that recovery is faster than rehabilitation alone.

Musculoskeletal injuries also differ from each other. A ruptured tendon, chronic tendinopathy, muscle tear and post-operative wound involve different structures and treatment plans. Grouping them under “healing” hides clinically important differences.

What are the safety concerns?

There is no adequate human safety dataset for the TB-500 fragment. Unknowns include immune reactions, contaminants, peptide-related impurities, effects of repeated exposure and interactions with medicines or medical conditions.

The FDA highlights possible immunogenicity and manufacturing complexity. Immunogenicity means the potential to provoke an immune response. This can depend on aggregation, impurities, route and formulation as well as the amino-acid sequence itself.

Full-length thymosin beta-4 has been studied for blood-vessel formation and cell movement. Those processes are useful in repair but are also relevant to tumour biology. Laboratory findings do not show that the peptide causes cancer in people, but the absence of long-term systemic human research means cancer-related risk has not been adequately resolved.

An unregulated vial adds product-level risks. The label may not identify the sequence correctly, and reported purity does not confirm sterility, endotoxin control or batch consistency.

What did the FDA find when it examined product identity and quality?

The FDA's 2026 briefing document gives unusually detailed insight into why TB-500 cannot be assessed from a name alone. The agency evaluated the free-base and acetate forms separately because it was unclear which substance had originally been nominated for compounding. In this context, the acetate form is the peptide supplied with acetate ions as a salt, while free base refers to the non-acetate form.

The nomination described TB-500 free base, while the supplied certificate of analysis referred to TB-500 acetate. A certificate of analysis, usually shortened to CoA, is a document reporting the tests and specifications for a particular batch. The FDA also found inconsistencies involving the stated chemical formula, molecular weight and identifying numbers.

For an injectable peptide, identity and purity are only part of quality. The FDA highlighted sterility, bacterial endotoxins, visible or microscopic particles, aggregation and peptide-related impurities. Endotoxins are inflammatory substances from the outer membrane of certain bacteria. A product can contain no living bacteria and still cause a serious reaction if endotoxin control is inadequate.

Aggregation means peptide molecules have clumped together. Aggregates may reduce activity and can increase the chance of an immune response. Heat, acidity, concentration, excipients and manufacturing impurities can all affect aggregation. A single chromatography purity figure cannot answer every one of these questions.

The FDA concluded that the substances were not adequately characterised for the proposed compounded injections and that available nonclinical pharmacology did not support a wound-healing conclusion. It also found no nonclinical toxicity studies for the defined free-base or acetate forms and no human exposure data for the fragment.

These findings do not mean every material bearing the name is chemically identical or equally poor. They mean the public evidence was insufficient to establish consistent identity, injectable quality, safety and effectiveness.

Is TB-500 approved?

TB-500 is not an FDA-approved medicine. Full-length thymosin beta-4 is also not approved by the FDA as a general treatment for injury or recovery.

In July 2026, the FDA's Pharmacy Compounding Advisory Committee discussed TB-500-related bulk substances for possible inclusion on the section 503A bulks list. Section 503A is a part of US law governing certain traditional pharmacy compounding. An advisory discussion or vote is not FDA approval, and a compounded product is not an FDA-approved medicine.

The FDA's current public safety page states that the TB-500 nomination was withdrawn and records the agency's concerns about absent human exposure data, immune reactions and peptide impurities. Regulatory wording can change, so the current FDA source should be checked rather than relying on a clinic's description.

Is TB-500 prohibited in sport?

Yes. The 2026 World Anti-Doping Agency Prohibited List names thymosin beta-4 and its derivatives, including TB-500, under growth factors and growth-factor modulators. They are prohibited at all times, both in and out of competition.

The rule is separate from medicine approval. A substance can be prohibited in sport even when it is not an approved medicine, and an approved medicine can also be prohibited depending on the substance and circumstances.

What benefits are claimed, and what does the evidence support?

ClaimWhat the evidence supports
Faster tendon or ligament recoveryAnimal and mechanism research involving mainly full-length thymosin beta-4; no established clinical benefit for TB-500
Faster muscle recoveryNo dependable controlled human evidence for the fragment
Better wound healingSome animal and route-specific human research with full-length thymosin beta-4; not proof for injectable TB-500
Reduced inflammationLaboratory and animal findings; no general human anti-inflammatory indication
Treatment for colitisA 2026 full-length-peptide mouse study only; no human treatment evidence
Safe because it comes from a natural sequenceNot supported; a synthetic fragment and externally administered product create different exposures and manufacturing risks

How should the TB-500 evidence be ranked?

The research is easier to understand when it is separated by molecule, model and route. Combining every paper under one product name creates an impression of depth that the fragment does not have.

Evidence layerWhat was testedWhat it can tell us
BiochemistryFull-length thymosin beta-4, fragments and isolated proteinsWhich molecules bind or influence a pathway under controlled conditions
Cultured cellsCorneal, immune, connective-tissue and other cellsWhether a response is possible in a simplified system
Animal injury modelsMainly full-length thymosin beta-4 in skin, eye, ligament and inflammatory modelsWhether experimental repair effects occur in a whole animal
Topical human researchSpecific full-length eye or wound formulationsRoute-specific signals in small or mixed clinical programmes
Systemic human TB-500 researchNo established controlled programme for Ac-LKKTETQNo dependable estimate of benefit, exposure or safety

A higher layer does not make every lower-layer result irrelevant. It limits what can be claimed. An animal ligament result can support further ligament research, but it cannot provide a human recovery time. A topical eye study cannot validate systemic use.

Why does product identity matter so much?

Peptide names are not enough to identify a vial. Full-length thymosin beta-4 has a different molecular mass, sequence and three-dimensional behaviour from Ac-LKKTETQ. A laboratory can distinguish them using mass spectrometry and chromatography, but a customer-facing label may not provide those data.

Even a correct molecular mass is not complete proof. Two peptides can have the same mass but a different sequence, and incomplete chains can be close in mass to the intended product. Tandem mass spectrometry breaks the peptide into fragments and can provide stronger sequence evidence.

An analytical purity percentage usually reports the proportion of material detected by one method under stated conditions. It does not show whether the sample is sterile, contains bacterial endotoxin, has degraded during storage or delivers the stated amount after preparation.

The problem is especially important for TB-500 because the commercial name is used inconsistently. A study should report the actual sequence and form, not only the label.

Does actin binding prove that the fragment repairs tissue?

No. Full-length thymosin beta-4 binds actin through a region containing the LKKTET sequence. This helped researchers identify a biologically interesting part of the parent molecule.

However, the complete peptide has structural regions outside that short sequence. Those regions may affect stability, location, enzyme breakdown and interactions with other molecules. Removing them can preserve one laboratory interaction while changing the behaviour of the molecule as a whole.

Tissue repair also depends on the order and timing of events. Early inflammation helps remove damaged material, while later inflammation can delay healing. New blood vessels can support repair, but poorly controlled vessel growth is not desirable everywhere. A peptide that changes one step does not automatically improve the final strength or function of the tissue.

What is known about distribution and breakdown?

Direct human pharmacokinetic data for TB-500 have not been established. Pharmacokinetics describes how a substance is absorbed, distributed, changed and removed.

Peptides can be broken down by proteases, the enzymes that cut peptide bonds. The resulting fragments may be inactive, retain part of the activity or produce a different signal. Anti-doping researchers have examined TB-500 metabolism outside the body to identify markers that might be detected in blood or urine. That work is analytical, not therapeutic.

Without a validated human assay and controlled exposure study, claims about a long systemic half-life are speculative. A half-life is the time required for the measured amount to fall by half.

The best-defined breakdown work comes from anti-doping research. Investigators identified the parent Ac-LKKTETQ peptide and shorter metabolites in samples from horses. The fragment was progressively shortened from its C-terminal end, meaning amino acids were removed from the end of the chain opposite the acetylated beginning.

Laboratory experiments using human serum, kidney microsomes and liver preparations also found rapid cleavage into shorter products. Microsomes are small membrane fragments prepared from cells and used to study how enzymes may process a substance. They are not a complete human body and cannot supply a clinical half-life.

Detection research answers a narrow question: whether the original peptide or a breakdown product can be measured. It does not show that a detected level is effective, safe or capable of reaching an injured tendon.

Does thymosin beta-4 research raise a cancer question?

Full-length thymosin beta-4 has been studied in relation to cell migration, blood-vessel formation and tissue remodelling. These processes are part of normal repair. Tumours can also use them to grow and spread.

That overlap is a reason for long-term safety research, not proof that TB-500 causes cancer. The fragment has not been adequately studied in people with or without cancer. It is therefore equally unjustified to declare it carcinogenic or cancer-safe.

People sometimes cite laboratory papers in which thymosin beta-4 expression was associated with aggressive tumours. Association means two features occurred together. It does not show that externally administered peptide initiated the cancer. Tumour cells can increase many proteins as they change.

What would a credible injury trial look like?

A useful trial would begin with a defined injury, such as a particular grade of tendon disorder confirmed by clinical assessment and imaging. Participants would be randomly assigned to a characterised TB-500 product or a matched placebo alongside the same rehabilitation programme.

Researchers would choose the main outcome before the trial. This might be validated pain and function at a set time, return to activity under clear criteria or tissue strength after surgery. Imaging alone would be insufficient because structural appearances do not always match symptoms or function.

The trial would report product sequence, purity, sterility, exposure, adverse events and losses to follow-up. It would also need enough participants and follow-up to identify delayed healing, re-injury, immune reactions and other harms.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is TB-500 a peptide?

Yes. The material identified by anti-doping researchers is an acetylated chain of seven amino acids.

Is TB-500 full-length thymosin beta-4?

No. Full-length thymosin beta-4 has 43 amino acids. TB-500 is generally identified as the Ac-LKKTETQ fragment, although commercial naming is inconsistent.

Does TB-500 heal tendons?

There is no dependable controlled human evidence showing that the TB-500 fragment heals tendon injuries.

Has TB-500 been tested in clinical trials?

The FDA says it has not identified human exposure data for products containing the fragment. Human eye and wound research used specific full-length thymosin beta-4 formulations.

What did the 2026 colitis study test?

It tested recombinant full-length human thymosin beta-4 in mice with experimental colitis and intestinal fibrosis. It did not test TB-500 or people with inflammatory bowel disease.

What did the 2026 Achilles-tendon study test?

It tested a commercial product described as TB-500 in 32 rats after surgical Achilles-tendon cutting and repair. The paper reported improved four-week tissue scores and maximum load to failure, but did not provide enough chemical detail to confirm the product's sequence and did not test people.

Has full-length thymosin beta-4 been given intravenously to people?

Yes. Defined synthetic and recombinant full-length products have been examined in controlled Phase 1 safety studies, and a 2025 study involved 96 heart-attack patients. Those studies did not test the seven-amino-acid fragment or sports injuries.

Do the eye and heart trials show that TB-500 works?

No. They tested specific full-length thymosin beta-4 formulations. Their results cannot be transferred to Ac-LKKTETQ or to a different route and medical purpose.

Is there fragment-specific animal evidence?

Yes, but it remains limited. A 2003 study tested an LKKTETQ peptide in aged mice with skin wounds, and a 2026 rat tendon paper used a product labelled TB-500. Neither provides controlled human evidence.

Is TB-500 FDA approved?

No. It is not an FDA-approved medicine.

Is TB-500 banned in sport?

Yes. Thymosin beta-4 and its derivatives, including TB-500, are prohibited at all times under World Anti-Doping Agency rules.

How is TB-500 made?

The short fragment can be assembled from protected amino-acid building blocks using solid-phase peptide synthesis, then purified and analytically tested.

Is TB-500 the same as BPC-157?

No. They have different sequences, origins and research records. Neither compound's evidence can be used to validate the other.

Is there an established safe administration level?

No established human administration level exists for the fragment. Levels used in full-length topical studies do not transfer to other molecules or routes.

What the evidence supports today

Thymosin beta-4 has credible biochemical importance and a substantial preclinical research record. Specific full-length formulations have reached human eye and wound studies, with mixed and incomplete development outcomes.

TB-500 is a shorter fragment with a far smaller evidence base. The strongest current conclusion is not that it is a proven recovery treatment, but that claims about it routinely borrow evidence from a different molecule. The August 2026 colitis study reinforces that lesson because it used recombinant full-length thymosin beta-4 in mice.

Future research would need to define the tested molecule, verify product quality, use clinically meaningful outcomes and follow participants long enough to assess harms as well as possible benefits.

RESEARCH AND MEDICAL NOTICE

This guide explains published and regulatory evidence. It does not recommend using TB-500, thymosin beta-4 or any unapproved product. It does not provide personal dosing, administration, cycling, stacking or injury-treatment instructions.

RESEARCH LIBRARY

Sources

Primary evidenceWorld Anti-Doping Agency
World Anti-Doping Agency: TB-500 identity, metabolism and detectionOpen source →
Primary evidenceWorld Anti-Doping Agency
World Anti-Doping Agency 2026 Prohibited ListOpen source →
Primary evidenceFDA
FDA: substances that may present significant compounding safety risksOpen source →
Primary evidenceFDA
FDA 2026 TB-500 briefing documentOpen source →
Primary evidenceFDA
FDA July 2026 Pharmacy Compounding Advisory Committee meetingOpen source →
Primary evidencePubMed
Thymosin beta-4 and rat wound healingOpen source →
Primary evidencePubMed
Thymosin beta-4, angiogenesis and wound repairOpen source →
Primary evidencePubMed
Thymosin beta-4 and corneal wound healingOpen source →
Primary evidencePubMed
Thymosin beta-4 and experimental ligament repairOpen source →
Primary evidencePubMed
Full-length thymosin beta-4 and LKKTETQ in diabetic and aged mouse woundsOpen source →
Primary evidencePubMed
2026 TB-500 and BPC-157 rat Achilles-tendon studyOpen source →
Primary evidencejointdrs.org
Full text of the 2026 rat Achilles-tendon studyOpen source →
Primary evidencePubMed
Thymosin beta-4 and muscle-cell movement after mouse injuryOpen source →
Primary evidencePubMed
Thymosin beta-4 as an exercise-related signal and negative mouse regeneration resultOpen source →
Primary evidencePubMed
Full-length thymosin beta-4 and mouse fracture healingOpen source →
Primary evidencePubMed
Phase 2 thymosin beta-4 dry-eye trialOpen source →
Primary evidencePubMed
Phase 2 thymosin beta-4 controlled-environment dry-eye trialOpen source →
Primary evidencePubMed
Phase 3 RGN-259 neurotrophic-keratopathy trialOpen source →
Primary evidencePubMed
2025 systematic review of neurotrophic-keratopathy treatmentsOpen source →
Primary evidenceClinicalTrials.gov
Registered dry-eye trial NCT01393132Open source →
Primary evidencePubMed
Phase 2 full-length thymosin beta-4 venous-ulcer trialOpen source →
Primary evidencePubMed
2010 placebo-controlled Phase 1 intravenous thymosin beta-4 studyOpen source →
Primary evidenceClinicalTrials.gov
Registered Phase 1 intravenous thymosin beta-4 studyOpen source →
Primary evidencePubMed
2021 Phase 1 recombinant full-length thymosin beta-4 studyOpen source →
Primary evidencePubMed
2025 randomised full-length thymosin beta-4 heart studyOpen source →
Primary evidencePubMed
Review of thymosin beta-4 dermal healing researchOpen source →
Primary evidencePubMed
Thymosin beta-4 regenerative biology reviewOpen source →
Primary evidencePubMed
Thymosin beta-4 eye-development reviewOpen source →
Primary evidencePubMed
Identification of Ac-LKKTETQ in TB-500Open source →
Primary evidencePubMed
Equine detection of TB-500 and its metabolitesOpen source →
Primary evidencePubMed
TB-500 metabolism in human laboratory preparationsOpen source →
Primary evidencePubMed
2026 recombinant thymosin beta-4 colitis studyOpen source →
Primary evidencelink.springer.com
Full open-access 2026 colitis paperOpen source →

Research reviewed through 17 November 2026.